Brilinta Taiwan Post Approval Safety Study

• Status: Completed
• Trial end date: 2017-02-09
• Target enrollment: 0
• Participant gender: All

Summary

A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the eletrocardiogram which presents the period when ventricles are depolarized) elevation myocardial infarction

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Ticagrelor

Criteria

Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedures

2. Female or male aged at least 20 years

3. Patient who is considered as ethnic Taiwanese

4. Index event of non-ST elevation myocardial infarction

Exclusion Criteria:

1. Contraindication or other reason that ticagrelor should not be administered

2. Index event is an acute complication of Percutaneous coronary intervention (PCI)

3. Patient has planned for an urgent coronary artery bypass graft (CABG) within 7 days from the enrolment

4. Oral anticoagulation therapy within 30 days prior to enrolment or cannot be stopped

5. Fibrinolytic therapy in the 24 hours prior to enrolment, or planned fibrinolytic treatment following enrolment